Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 20/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239111 | 1.00 | P2RX4 (0.55) | P2RX4HTR2CDRD3 | |
| SCHEMBL16267239 | 0.89 | P2RX4 (0.62) | P2RX4 | |
| SCHEMBL16239312 | 0.85 | P2RX4 (0.72) | P2RX4 | |
| SCHEMBL16238942 | 0.82 | P2RX4 (0.52) | P2RX4 | |
| SCHEMBL29908756 | 0.82 | P2RX4 (0.58) | P2RX4 | |
| SCHEMBL16239067 | 0.82 | P2RX4 (0.58) | P2RX4 | |
| SCHEMBL29908782 | 0.80 | P2RX4 (0.59) | P2RX4 | |
| SCHEMBL16239091 | 0.80 | P2RX4 (0.59) | P2RX4 | |
| SCHEMBL16238922 | 0.79 | P2RX4 (0.60) | P2RX4HTR2CDRD3 | |
| SCHEMBL16239135 | 0.79 | P2RX4 (0.54) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HTR2C 129/4885DRD3 371/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 5/4885HTR2C 114/4885DRD3 328/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HTR2C 129/4885DRD3 371/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885HTR2C 129/4885DRD3 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.